PRQR · ProQR Therapeutics N.V.

ProQR Therapeutics’ Q1 2026 results reflect sustained investment in its Axiomer™ RNA editing platform amid strategic pipeline prioritization and operational execution. Net loss widened to €13.4 million from €10.1 million year-over-year, driven primarily by higher general and administrative expenses (€3.9M vs. €3.2M), partially offset by lower R&D spend (€11.8M vs. €12.3M). Revenue declined to €2.0M from €4.5M, consistent with the company’s clinical-stage profile and absence of commercial products. Management attributes the expense profile to ongoing development of AX-0810, advancement of next-generation candidates (AX-0811, AX-0422, AX-2911), and infrastructure investments—including the Ginkgo Bioworks partnership and AI Advisory Board formation—to accelerate discovery. The shift to biliary atresia as AX-0810’s initial Phase 2 indication signals a deliberate focus on high-unmet-need pediatric populations and earlier clinical data generation via an investigator-initiated trial in China, with readouts targeted for H1 2027. Cash of €81.1 million at quarter-end—down €11.3 million from December 31, 2025—aligns with €11.1 million in operating cash outflow and supports the stated runway into mid-2027. This runway enables delivery of multiple near-term milestones: AX-0810 target engagement data in Q2 2026, AX-0811 CTA filing mid-2026, and progression of three additional programs toward clinical testing. The nomination of Dr. Lykke Hinsch Gylvin—a seasoned Boehringer Ingelheim executive—to the Board further strengthens governance ahead of pivotal clinical and strategic inflection points. Collectively, these developments underscore ProQR’s transition from platform validation to focused clinical execution, with material value hinges on successful translation of target engagement data into clinical proof-of-concept.